CAMK2G and myocardial infarction: STZ-treated MM-VV mice and mice with transgenic myocardial and SAN expression of AC3-I (Zhang et al., 2005) were protected from increased mortality after MI, indicating that increased ox-CaMKII was essential for excess mortality after MI in STZ-treated mice.